imiquimod
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma
Conditions
Basal Cell Carcinoma
Trial Timeline
Feb 1, 2001 → Feb 1, 2007
NCT ID
NCT00189241About imiquimod
imiquimod is a phase 3 stage product being developed by Viatris for Basal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00189241. Target conditions include Basal Cell Carcinoma.
What happened to similar drugs?
1 of 6 similar drugs in Basal Cell Carcinoma were approved
Approved (1) Terminated (2) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189293 | Approved | Completed |
| NCT00189254 | Pre-clinical | Completed |
| NCT00189280 | Phase 3 | Completed |
| NCT00189241 | Phase 3 | Completed |
Competing Products
20 competing products in Basal Cell Carcinoma